{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T22:49:57Z","timestamp":1773182997983,"version":"3.50.1"},"reference-count":140,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1053\/j.seminhematol.2024.09.006","type":"journal-article","created":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T15:36:30Z","timestamp":1726932990000},"page":"397-408","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cellular and immunotherapies for myelodysplastic syndromes"],"prefix":"10.1053","volume":"61","author":[{"given":"Ryan J.","family":"Stubbins","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"Cherniawsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aly","family":"Karsan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1053\/j.seminhematol.2024.09.006_bib0001","doi-asserted-by":"crossref","first-page":"e1786","DOI":"10.1002\/onco.13887","article-title":"Systematic review of PD-1\/PD-L1 inhibitors in oncology: from personalized medicine to public health","volume":"26","author":"Chang","year":"2021","journal-title":"Oncologist"},{"issue":"14","key":"10.1053\/j.seminhematol.2024.09.006_bib0002","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood.2022018730","article-title":"Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study","volume":"141","author":"Abramson","year":"2023","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.09.006_bib0003","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-Cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.09.006_bib0004","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1056\/NEJM197909133011109","article-title":"Marrow transplantation for acute nonlymphoblastic leukemia in first remission","volume":"301","author":"Thomas","year":"1979","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1053\/j.seminhematol.2024.09.006_bib0005","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1182\/blood.2022017795","article-title":"Flotetuzumab and other T-cell immunotherapies upregulate MHC class II expression on acute myeloid leukemia cells","volume":"141","author":"Rimando","year":"2023","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.09.006_bib0006","doi-asserted-by":"crossref","first-page":"e003149","DOI":"10.1136\/jitc-2021-003149","article-title":"Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design","volume":"9","author":"Qin","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.09.006_bib0007","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1002\/eji.202049064","article-title":"CAR T cells: building on the CD19 paradigm","volume":"51","author":"Globerson Levin","year":"2021","journal-title":"Eur J Immunol"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.09.006_bib0008","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1182\/blood.2021015162","article-title":"Inflammation and myeloid malignancy: quenching the flame","volume":"140","author":"Stubbins","year":"2022","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.09.006_bib0009","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1365-2141.2011.08872.x","article-title":"T cells of patients with myelodysplastic syndrome are frequently derived from the malignant clone","volume":"156","author":"Vercauteren","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2024.09.006_bib0010","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.3389\/fimmu.2020.01236","article-title":"Contribution of Aberrant toll like receptor signaling to the pathogenesis of myelodysplastic syndromes","volume":"11","author":"Paracatu","year":"2020","journal-title":"Front Immunol"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.09.006_bib0011","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.3324\/haematol.2016.158857","article-title":"Pro-inflammatory proteins S100A9 and tumor necrosis factor-\u03b1 suppress erythropoietin elaboration in myelodysplastic syndromes","volume":"102","author":"Cluzeau","year":"2017","journal-title":"Haematologica"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.09.006_bib0012","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1158\/1078-0432.CCR-06-2108","article-title":"Toll-like receptor-4 is up-regulated in hematopoietic progenitor cells and contributes to increased apoptosis in myelodysplastic syndromes","volume":"13","author":"Maratheftis","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.09.006_bib0013","doi-asserted-by":"crossref","first-page":"e71120","DOI":"10.1371\/journal.pone.0071120","article-title":"Overexpression of the toll-like receptor (TLR) signaling adaptor MYD88, but lack of genetic mutation, in myelodysplastic syndromes","volume":"8","author":"Dimicoli","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.09.006_bib0014","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ccr.2013.05.006","article-title":"Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome","volume":"24","author":"Rhyasen","year":"2013","journal-title":"Cancer Cell"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.09.006_bib0015","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1182\/blood.V100.10.3553","article-title":"Characterization of gene expression of CD34+ cells from normal and myelodysplastic bone marrow","volume":"100","author":"Hofmann","year":"2002","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.09.006_bib0016","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20200731","article-title":"TIRAP drives myelosuppression through an Ifn\u03b3-Hmgb1 axis that disrupts the endothelial niche in mice","volume":"219","author":"Gopal","year":"2022","journal-title":"J Exp Med"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.09.006_bib0017","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/s41556-019-0314-5","article-title":"U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies","volume":"21","author":"Smith","year":"2019","journal-title":"Nat Cell Biol"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.09.006_bib0018","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nm.2054","article-title":"Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype","volume":"16","author":"Starczynowski","year":"2010","journal-title":"Nat Med"},{"issue":"25","key":"10.1053\/j.seminhematol.2024.09.006_bib0019","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1182\/blood-2016-07-730556","article-title":"The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype","volume":"128","author":"Basiorka","year":"2016","journal-title":"Blood"},{"issue":"21","key":"10.1053\/j.seminhematol.2024.09.006_bib0020","doi-asserted-by":"crossref","first-page":"9626","DOI":"10.18632\/aging.102409","article-title":"Cellular senescence induced by S100A9 in mesenchymal stromal cells through NLRP3 inflammasome activation","volume":"11","author":"Shi","year":"2019","journal-title":"Aging (Albany NY)"},{"issue":"25","key":"10.1053\/j.seminhematol.2024.09.006_bib0021","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1182\/blood.2019003105","article-title":"Altered microRNA expression links IL6 and TNF-induced inflammaging with myeloid malignancy in humans and mice","volume":"135","author":"Grants","year":"2020","journal-title":"Blood"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.09.006_bib0022","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1084\/jem.20110752","article-title":"Tumor necrosis factor restricts hematopoietic stem cell activity in mice: involvement of two distinct receptors","volume":"208","author":"Pronk","year":"2011","journal-title":"J Exp Med"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.09.006_bib0023","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1182\/blood-2014-04-570762","article-title":"Endothelial cells translate pathogen signals into G-CSF-driven emergency granulopoiesis","volume":"124","author":"Boettcher","year":"2014","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.09.006_bib0024","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.stem.2016.08.021","article-title":"Mesenchymal inflammation drives genotoxic stress in hematopoietic stem cells and predicts disease evolution in human pre-leukemia","volume":"19","author":"Zambetti","year":"2016","journal-title":"Cell Stem Cell"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.09.006_bib0025","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/leu.2011.251","article-title":"IPSS-independent prognostic value of plasma CXCL10, IL-7 and IL-6 levels in myelodysplastic syndromes","volume":"26","author":"Pardanani","year":"2012","journal-title":"Leukemia"},{"issue":"538","key":"10.1053\/j.seminhematol.2024.09.006_bib0026","doi-asserted-by":"crossref","first-page":"eaax5104","DOI":"10.1126\/scitranslmed.aax5104","article-title":"IL-6 blockade reverses bone marrow failure induced by human acute myeloid leukemia","volume":"12","author":"Zhang","year":"2020","journal-title":"Sci Transl Med"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.09.006_bib0027","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/bloodadvances.2021004379","article-title":"Anti-IL-6 cytokine treatment has no impact on elevated hematocrit or splenomegaly in a polycythemia vera mouse model","volume":"6","author":"Baldauf","year":"2022","journal-title":"Blood Adv"},{"issue":"13","key":"10.1053\/j.seminhematol.2024.09.006_bib0028","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1016\/j.celrep.2017.03.018","article-title":"Identification of interleukin-1 by functional screening as a key mediator of cellular expansion and disease progression in acute myeloid leukemia","volume":"18","author":"Carey","year":"2017","journal-title":"Cell Rep"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.09.006_bib0029","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1182\/blood-2012-01-404699","article-title":"Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS","volume":"120","author":"Barreyro","year":"2012","journal-title":"Blood"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.09.006_bib0030","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.1172\/JCI67580","article-title":"Induction of myelodysplasia by myeloid-derived suppressor cells","volume":"123","author":"Chen","year":"2013","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.09.006_bib0031","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1038\/s41467-018-04831-3","article-title":"miR-143\/145 differentially regulate hematopoietic stem and progenitor activity through suppression of canonical TGF\u03b2 signaling","volume":"9","author":"Lam","year":"2018","journal-title":"Nat Commun"},{"issue":"13","key":"10.1053\/j.seminhematol.2024.09.006_bib0032","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1056\/NEJMoa1910182","article-title":"A phase 3 trial of luspatercept in patients with transfusion-dependent \u03b2-thalassemia","volume":"382","author":"Cappellini","year":"2020","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1053\/j.seminhematol.2024.09.006_bib0033","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1182\/blood.2023023166","article-title":"T-cell dysfunctions in myelodysplastic syndromes","volume":"143","author":"Rodriguez-Sevilla","year":"2024","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.09.006_bib0034","article-title":"The multifaceted roles of CD4","volume":"83","author":"Bawden","year":"2023","journal-title":"Curr Opin Immunol"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.09.006_bib0035","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1365-2141.2009.07593.x","article-title":"IL-17-producing CD4(+) T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome","volume":"145","author":"Kordasti","year":"2009","journal-title":"Br J Haematol"},{"issue":"24","key":"10.1053\/j.seminhematol.2024.09.006_bib0036","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1182\/blood.2020006158","article-title":"TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype","volume":"136","author":"Sallman","year":"2020","journal-title":"Blood"},{"issue":"25","key":"10.1053\/j.seminhematol.2024.09.006_bib0037","doi-asserted-by":"crossref","first-page":"14331","DOI":"10.1073\/pnas.1916206117","article-title":"Reversible suppression of T cell function in the bone marrow microenvironment of acute myeloid leukemia","volume":"117","author":"Lamble","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.09.006_bib0038","doi-asserted-by":"crossref","first-page":"e220","DOI":"10.3324\/haematol.2014.116657","article-title":"Regulatory T cells and progenitor B cells are independent prognostic predictors in lower risk myelodysplastic syndromes","volume":"100","author":"Kahn","year":"2015","journal-title":"Haematologica"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.09.006_bib0039","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/leu.2008.333","article-title":"Kinetics, function and bone marrow trafficking of CD4+CD25+FOXP3+ regulatory T cells in myelodysplastic syndromes (MDS)","volume":"23","author":"Kotsianidis","year":"2009","journal-title":"Leukemia"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.09.006_bib0040","doi-asserted-by":"crossref","first-page":"655","DOI":"10.3324\/haematol.2020.268136","article-title":"Reduced frequencies and functional impairment of dendritic cell subsets and non-classical monocytes in myelodysplastic syndromes","volume":"107","author":"Van Leeuwen-Kerkhoff","year":"2022","journal-title":"Haematologica"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.09.006_bib0041","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1111\/jcmm.14825","article-title":"CD8+ T cells exhaustion induced by myeloid-derived suppressor cells in myelodysplastic syndromes patients might be through TIM3\/Gal-9 pathway","volume":"24","author":"Tao","year":"2020","journal-title":"J Cell Mol Med"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.09.006_bib0042","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1080\/10428194.2020.1817431","article-title":"Increased myeloid-derived suppressor cells in patients with myelodysplastic syndromes suppress CD8+ T lymphocyte function through the STAT3-ARG1 pathway","volume":"62","author":"Qi","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.09.006_bib0043","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1062208","article-title":"Expansion of myeloid derived suppressor cells correlates with number of T regulatory cells and disease progression in myelodysplastic syndrome","volume":"5","author":"Kittang","year":"2016","journal-title":"Oncoimmunology"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.09.006_bib0044","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1007\/s00262-019-02420-x","article-title":"Tumor genetic alterations and features of the immune microenvironment drive myelodysplastic syndrome escape and progression","volume":"68","author":"Montes","year":"2019","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.09.006_bib0045","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.130155","article-title":"Mesenchymal stromal cells shape the MDS microenvironment by inducing suppressive monocytes that dampen NK cell function","volume":"5","author":"Sarhan","year":"2020","journal-title":"JCI Insight"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.09.006_bib0046","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1073\/pnas.1222861110","article-title":"Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes","volume":"110","author":"Pang","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.seminhematol.2024.09.006_bib0047","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.950134","article-title":"Dynamics of PD-1 expression are associated with treatment efficacy and prognosis in patients with intermediate\/high-risk myelodysplastic syndromes under hypomethylating treatment","volume":"13","author":"Geng","year":"2022","journal-title":"Front Immunol"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.09.006_bib0048","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/leu.2013.355","article-title":"Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents","volume":"28","author":"Yang","year":"2014","journal-title":"Leukemia"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.09.006_bib0049","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1038\/s41375-019-0397-9","article-title":"S100A9-induced overexpression of PD-1\/PD-L1 contributes to ineffective hematopoiesis in myelodysplastic syndromes","volume":"33","author":"Cheng","year":"2019","journal-title":"Leukemia"},{"issue":"51","key":"10.1053\/j.seminhematol.2024.09.006_bib0050","doi-asserted-by":"crossref","first-page":"88904","DOI":"10.18632\/oncotarget.21492","article-title":"Functional expression of Tim-3 on blasts and clinical impact of its ligand galectin-9 in myelodysplastic syndromes","volume":"8","author":"Asayama","year":"2017","journal-title":"Oncotarget"},{"issue":"32","key":"10.1053\/j.seminhematol.2024.09.006_bib0051","doi-asserted-by":"crossref","first-page":"33823","DOI":"10.18632\/oncotarget.5257","article-title":"Differential expression and biochemical activity of the immune receptor Tim-3 in healthy and malignant human myeloid cells","volume":"6","author":"Gon\u00e7alves Silva","year":"2015","journal-title":"Oncotarget"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.09.006_bib0052","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/imm.12665","article-title":"Functional exhaustion of CD4+ T cells induced by co-stimulatory signals from myeloid leukaemia cells","volume":"149","author":"Ozkazanc","year":"2016","journal-title":"Immunology"},{"key":"10.1053\/j.seminhematol.2024.09.006_bib0053","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.leukres.2016.11.003","article-title":"Increased TIM3+CD8+T cells in Myelodysplastic Syndrome patients displayed less perforin and granzyme B secretion and higher CD95 expression","volume":"51","author":"Tao","year":"2016","journal-title":"Leuk Res"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.09.006_bib0054","doi-asserted-by":"crossref","DOI":"10.1080\/16078454.2023.2166333","article-title":"Myeloid-derived suppressor cells inhibit natural killer cells in myelodysplastic syndromes through the TIGIT\/CD155 pathway","volume":"28","author":"Yue","year":"2023","journal-title":"Hematology"},{"key":"10.1053\/j.seminhematol.2024.09.006_bib0055","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.3389\/fonc.2020.01595","article-title":"Overexpression of TIGIT in NK and T cells contributes to tumor immune escape in myelodysplastic syndromes","volume":"10","author":"Meng","year":"2020","journal-title":"Front Oncol"},{"key":"10.1053\/j.seminhematol.2024.09.006_bib0056","doi-asserted-by":"crossref","DOI":"10.1155\/2023\/1972127","article-title":"High co-expression of PDCD1\/TIGIT\/ CD47\/ KIR3DL2 in bone marrow is associated with poor prognosis for patients with myelodysplastic syndrome","volume":"2023","author":"Zhong","year":"2023","journal-title":"J Oncol"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.09.006_bib0057","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/s41409-022-01620-x","article-title":"Impact of in vivo T-cell depletion in patients with myelodysplastic syndromes undergoing allogeneic hematopoietic stem cell transplant: a registry study from the Chronic Malignancies Working Party of the EBMT","volume":"57","author":"Forcade","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.09.006_bib0058","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1182\/blood.V83.4.1060.1060","article-title":"Recognition of minor histocompatibility antigens on lymphocytic and myeloid leukemic cells by cytotoxic T-cell clones","volume":"83","author":"van der Harst","year":"1994","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.09.006_bib0059","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2023.101476","article-title":"Graft versus leukemia in 2023","volume":"36","author":"Chiad","year":"2023","journal-title":"Best Pract Res Clin Haematol"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.09.006_bib0060","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/BF00185109","article-title":"Immunogenetics of human minor histocompatibility antigens: their polymorphism and immunodominance","volume":"35","author":"van Els","year":"1992","journal-title":"Immunogenetics"},{"key":"10.1053\/j.seminhematol.2024.09.006_bib0061","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1202950","article-title":"Beyond \u03b1\u03b2 T cells: NK, iNKT, and \u03b3\u03b4T cell biology in leukemic patients and potential for off-the-shelf adoptive cell therapies for AML","volume":"14","author":"Kent","year":"2023","journal-title":"Front Immunol"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.09.006_bib0062","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1067\/mai.2002.124259","article-title":"T-cell activation through the antigen receptor. Part 1: signaling components, signaling pathways, and signal integration at the T-cell antigen receptor synapse","volume":"109","author":"Nel","year":"2002","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.09.006_bib0063","doi-asserted-by":"crossref","first-page":"646","DOI":"10.7326\/0003-4819-120-8-199404150-00004","article-title":"Identical-twin bone marrow transplants for leukemia","volume":"120","author":"Gale","year":"1994","journal-title":"Ann Intern Med"},{"issue":"13","key":"10.1053\/j.seminhematol.2024.09.006_bib0064","doi-asserted-by":"crossref","first-page":"4560","DOI":"10.1182\/blood-2007-06-095265","article-title":"The importance of HLA-DPB1 in unrelated donor hematopoietic cell transplantation","volume":"110","author":"Shaw","year":"2007","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.09.006_bib0065","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41409-019-0694-y","article-title":"Protective effect of HLA-DPB1 mismatch remains valid in reduced-intensity conditioning unrelated donor hematopoietic cell transplantation","volume":"55","author":"Malki","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"24","key":"10.1053\/j.seminhematol.2024.09.006_bib0066","doi-asserted-by":"crossref","first-page":"6483","DOI":"10.1158\/1078-0432.CCR-20-1104","article-title":"Effects of acute and chronic graft-versus-myelodysplastic syndrome on long-term outcomes following allogeneic hematopoietic cell transplantation","volume":"26","author":"Konuma","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.09.006_bib0067","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.3390\/cancers16071278","article-title":"Donor lymphocyte infusion in the treatment of post-transplant relapse of acute myeloid leukemias and myelodysplastic syndromes significantly improves overall survival: a French-Italian experience of 134 patients","volume":"16","author":"Accorsi Buttini","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.09.006_bib0068","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/s41409-024-02282-7","article-title":"Reduced intensity versus myeloablative conditioning for MDS: long-term results of an EBMT phase III study (RICMAC)","volume":"59","author":"Niederwieser","year":"2024","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.09.006_bib0069","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood-2016-09-737700","article-title":"Genome-wide minor histocompatibility matching as related to the risk of graft-versus-host disease","volume":"129","author":"Martin","year":"2017","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.09.006_bib0070","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1182\/blood-2011-11-394395","article-title":"Mutated regions of nucleophosmin 1 elicit both CD4(+) and CD8(+) T-cell responses in patients with acute myeloid leukemia","volume":"120","author":"Greiner","year":"2012","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.09.006_bib0071","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1182\/blood.V95.7.2198","article-title":"Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1","volume":"95","author":"Gao","year":"2000","journal-title":"Blood"},{"issue":"24","key":"10.1053\/j.seminhematol.2024.09.006_bib0072","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa1808777","article-title":"Immune escape of relapsed AML cells after allogeneic transplantation","volume":"379","author":"Christopher","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.09.006_bib0073","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41591-019-0400-z","article-title":"Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation","volume":"25","author":"Toffalori","year":"2019","journal-title":"Nat Med"},{"issue":"15","key":"10.1053\/j.seminhematol.2024.09.006_bib0074","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1182\/blood-2009-11-254284","article-title":"Relapse of leukemia with loss of mismatched HLA resulting from uniparental disomy after haploidentical hematopoietic stem cell transplantation","volume":"115","author":"Villalobos","year":"2010","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.09.006_bib0075","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1080\/10428194.2022.2034155","article-title":"Pembrolizumab for myelodysplastic syndromes after failure of hypomethylating agents in the phase 1b KEYNOTE-013 study","volume":"63","author":"Garcia-Manero","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.09.006_bib0076","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1182\/bloodadvances.2021005240","article-title":"Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndrome","volume":"6","author":"Gerds","year":"2022","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.09.006_bib0077","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1182\/blood-2018-99-119424","article-title":"A phase II study of nivolumab or ipilimumab with or without azacitidine for patients with myelodysplastic syndrome (MDS)","volume":"132","author":"Garcia-Manero","year":"2018","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.09.006_bib0078","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/bjh.17689","article-title":"Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome","volume":"195","author":"Chien","year":"2021","journal-title":"Br J Haematol"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.09.006_bib0079","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2020-142003","article-title":"A Phase II study of double immune checkpoint inhibitor blockade with nivolumab and ipilimumab with or without azacitidine in P","volume":"136","author":"Morita","year":"2020","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.09.006_bib0080","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1182\/bloodadvances.2021005487","article-title":"A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes","volume":"6","author":"Zeidan","year":"2022","journal-title":"Blood Adv"},{"issue":"24","key":"10.1053\/j.seminhematol.2024.09.006_bib0081","doi-asserted-by":"crossref","first-page":"5306","DOI":"10.1158\/1078-0432.CCR-22-1810","article-title":"Safety, outcomes, and T-cell characteristics in patients with relapsed or refractory MDS or CMML treated with atezolizumab in combination with guadecitabine","volume":"28","author":"O'Connell","year":"2022","journal-title":"Clinical Cancer Research"},{"issue":"21","key":"10.1053\/j.seminhematol.2024.09.006_bib0082","doi-asserted-by":"crossref","first-page":"11538","DOI":"10.1128\/JVI.01967-13","article-title":"The role of interleukin-6 in the expression of PD-1 and PDL-1 on central nervous system cells following infection with Theiler's murine encephalomyelitis virus","volume":"87","author":"Jin","year":"2013","journal-title":"J Virol"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.09.006_bib0083","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1158\/2159-8290.CD-15-1347","article-title":"TGF\u03b21-mediated SMAD3 enhances PD-1 expression on antigen-specific T cells in cancer","volume":"6","author":"Park","year":"2016","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.09.006_bib0084","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1016\/S2352-3026(23)00333-2","article-title":"Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"11","author":"Zeidan","year":"2024","journal-title":"Lancet Haematol"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.09.006_bib0085","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2217\/fon-2022-1237","article-title":"STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453)\u202f+\u202fazacitidine in higher risk MDS and CMML-2","volume":"19","author":"Zeidan","year":"2023","journal-title":"Future Oncol"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.09.006_bib0086","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1182\/blood-2023-180876","article-title":"TIM-3 inhibitor sabatolimab for patients with acute myeloid leukemia (AML) with measurable residual disease (MRD) detected after allogeneic stem cell transplantation (AlloSCT): preliminary findings from the phase Ib\/II stimulus-AML2 study","volume":"14","author":"Zeiser","year":"2023","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.09.006_bib0087","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.09.006_bib0088","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.09.006_bib0089","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1038\/bcj.2014.39","article-title":"Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia","volume":"4","author":"Ehninger","year":"2014","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.09.006_bib0090","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1182\/blood.2020007732","article-title":"Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia","volume":"137","author":"Uy","year":"2021","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.09.006_bib0091","doi-asserted-by":"crossref","first-page":"11753","DOI":"10.1182\/blood-2022-159524","article-title":"A phase 1, first-in-human, dose-escalation study of MGD024, a CD123 x CD3 bispecific Dart\u00ae molecule, in patients with relapsed or refractory CD123-positive (+) hematologic malignancies","volume":"140","author":"Winer","year":"2022","journal-title":"Blood"},{"issue":"Supplement","key":"10.1053\/j.seminhematol.2024.09.006_bib0092","doi-asserted-by":"crossref","first-page":"V355","DOI":"10.1093\/annonc\/mdx373.001","article-title":"Interim results from a phase 1 first-in-human study of flotetuzumab, a CD123 x CD3 bispecific DART molecule, in AML\/MDS","volume":"28","author":"Vey","year":"2017","journal-title":"Annals Oncol"},{"issue":"21","key":"10.1053\/j.seminhematol.2024.09.006_bib0093","doi-asserted-by":"crossref","first-page":"5287","DOI":"10.3390\/cancers13215287","article-title":"Risk, characteristics and biomarkers of cytokine release syndrome in patients with relapsed\/refractory AML or MDS treated with CD3xCD123 bispecific antibody APVO436","volume":"13","author":"Uckun","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1053\/j.seminhematol.2024.09.006_bib0094","doi-asserted-by":"crossref","unstructured":"Nguyen D, Ravandi F, Wang SA, et al. A phase II study of vibecotamab, a CD3-CD123 bispecific T-cell engaging antibody, for MDS or CMML after hypomethylating failure and in MRD-Positive AML. 2023;142(Supplement 1):322.","DOI":"10.1182\/blood-2023-190693"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.09.006_bib0095","doi-asserted-by":"crossref","first-page":"e13742","DOI":"10.1111\/cts.13742","article-title":"First-in-human study of JNJ-67571244, a CD33\u202f\u00d7\u202fCD3 bispecific antibody, in relapsed\/refractory acute myeloid leukemia and myelodysplastic syndrome","volume":"17","author":"Narayan","year":"2024","journal-title":"Clin Transl Sci"},{"key":"10.1053\/j.seminhematol.2024.09.006_bib0096","first-page":"834","article-title":"Phase 1 first-in-human trial of AMV564, a bivalent bispecific (2:2) CD33\/CD3 T-Cell engager, in patients with relapsed\/refractory acute myeloid leukemia (AML)","volume":"134","author":"Westervelt","year":"2019"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.09.006_bib0097","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/s41556-018-0104-5","article-title":"Single-cell analysis identifies a single-cell analysis identifies a CD33+ subset of human cord blood cells with high regenerative potential","volume":"20","author":"Knapp","year":"2018","journal-title":"Nat Cell Biol"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.09.006_bib0098","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1038\/s41375-021-01232-2","article-title":"Autologous CD33-CAR-T cells for treatment of relapsed\/refractory acute myelogenous leukemia","volume":"35","author":"Tambaro","year":"2021","journal-title":"Leukemia"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.09.006_bib0099","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1182\/blood-2023-179667","article-title":"CD33 CAR T-cells (CD33CART) for children and young adults with relapsed\/refractory AML: dose-escalation results from a phase I\/II multicenter trial","volume":"142","author":"Shah","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.09.006_bib0100","doi-asserted-by":"crossref","first-page":"10313","DOI":"10.1182\/blood-2022-169142","article-title":"Phase 1\/1b safety study of Prgn-3006 Ultracar-T in patients with relapsed or refractory CD33-positive acute myeloid leukemia and higher risk myelodysplastic syndromes","volume":"140","author":"Sallman","year":"2022","journal-title":"Blood"},{"issue":"4_Supplement","key":"10.1053\/j.seminhematol.2024.09.006_bib0101","doi-asserted-by":"crossref","first-page":"PR14","DOI":"10.1158\/2326-6074.TUMIMM18-PR14","article-title":"CD123CAR displays clinical activity in relapsed\/refractory (r\/r) acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN): Safety and efficacy results from a phase 1 study","volume":"8","author":"Budde","year":"2020","journal-title":"Cancer Immunol Res"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.09.006_bib0102","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1182\/blood-2023-180387","article-title":"A phase I clinical trial of CLL-1 CAR-T cells for the treatment of relapsed\/refractory acute myeloid leukemia in adults","volume":"142","author":"Zhang","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.09.006_bib0103","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1158\/2326-6066.CIR-18-0307","article-title":"Phase I Trial of autologous CAR T cells targeting NKG2D ligands in patients with AML\/MDS and multiple myeloma","volume":"7","author":"Baumeister","year":"2019","journal-title":"Cancer Immunol Res"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.09.006_bib0104","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1016\/S2352-3026(22)00378-7","article-title":"CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial","volume":"10","author":"Sallman","year":"2023","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.09.006_bib0105","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s40164-022-00318-6","article-title":"CD7-directed CAR T-cell therapy: a potential immunotherapy strategy for relapsed\/refractory acute myeloid leukemia","volume":"11","author":"Cao","year":"2022","journal-title":"Exp Hematol Oncol"},{"key":"10.1053\/j.seminhematol.2024.09.006_bib0106","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.omto.2023.07.003","article-title":"Anti-CD117 CAR T cells incorporating a safety switch eradicate human acute myeloid leukemia and hematopoietic stem cells","volume":"30","author":"Magnani","year":"2023","journal-title":"Mol Ther Oncolytics"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.09.006_bib0107","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1111\/bjh.18971","article-title":"FLT3-directed UniCAR T-cell therapy of acute myeloid leukaemia","volume":"202","author":"Peschke","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2024.09.006_bib0108","doi-asserted-by":"crossref","DOI":"10.1016\/j.omto.2023.100751","article-title":"Bispecific CD33\/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia","volume":"31","author":"Boucher","year":"2023","journal-title":"Mol Ther Oncolytics"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.09.006_bib0109","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1158\/2643-3230.BCD-20-0208","article-title":"NOT-Gated CD93 CAR T cells effectively target AML with minimized endothelial cross-reactivity","volume":"2","author":"Richards","year":"2021","journal-title":"Blood Cancer Discov"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.09.006_bib0110","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/s41591-024-02826-w","article-title":"T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy","volume":"30","author":"Ghilardi","year":"2024","journal-title":"Nat Med"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.09.006_bib0111","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1001\/jamaoncol.2023.7182","article-title":"Features and factors associated with myeloid neoplasms after chimeric antigen receptor T-cell therapy","volume":"10","author":"Gurney","year":"2024","journal-title":"JAMA Oncol"},{"issue":"13","key":"10.1053\/j.seminhematol.2024.09.006_bib0112","doi-asserted-by":"crossref","first-page":"3471","DOI":"10.3390\/cancers15133471","article-title":"Clonal myeloid dysplasia following CAR T-cell therapy: chicken or the egg?","volume":"15","author":"Vainstein","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"15","key":"10.1053\/j.seminhematol.2024.09.006_bib0113","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1182\/bloodadvances.2021004554","article-title":"Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy","volume":"5","author":"Miller","year":"2021","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.09.006_bib0114","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/blood-2023-182522","article-title":"CAR19 therapy drives expansion of clonal hematopoiesis and associated cytopenias","volume":"142","author":"Hamilton","year":"2023","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.09.006_bib0115","doi-asserted-by":"crossref","first-page":"7033","DOI":"10.1200\/JCO.2024.42.16_suppl.7033","article-title":"Secondary myeloid malignancy after CAR T cell therapy for non-Hodgkin lymphoma (NHL)","volume":"42","author":"Habib","year":"2024","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.09.006_bib0116","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/s41591-019-0472-9","article-title":"T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant","volume":"25","author":"Chapuis","year":"2019","journal-title":"Nat Med"},{"issue":"18","key":"10.1053\/j.seminhematol.2024.09.006_bib0117","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1182\/blood-2017-06-791202","article-title":"Safety and persistence of WT1-specific T-cell receptor gene-transduced lymphocytes in patients with AML and MDS","volume":"130","author":"Tawara","year":"2017","journal-title":"Blood"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.09.006_bib0118","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1182\/blood.2024024105","article-title":"HA-1-targeted T cell receptor (TCR) T cell therapy for recurrent leukemia after hematopoietic stem cell transplantation","volume":"144","author":"Krakow","year":"2024","journal-title":"Blood"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.09.006_bib0119","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41568-022-00491-0","article-title":"Natural killer cells in antitumour adoptive cell immunotherapy","volume":"22","author":"Laskowski","year":"2022","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.09.006_bib0120","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.bbmt.2009.01.018","article-title":"What is the role for donor natural killer cells after nonmyeloablative conditioning?","volume":"15","author":"Baron","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5562","key":"10.1053\/j.seminhematol.2024.09.006_bib0121","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1126\/science.1068440","article-title":"Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants","volume":"295","author":"Ruggeri","year":"2002","journal-title":"Science"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.09.006_bib0122","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1182\/blood-2006-07-038687","article-title":"Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value","volume":"110","author":"Ruggeri","year":"2007","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.09.006_bib0123","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1056\/NEJMoa1200503","article-title":"HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1","volume":"367","author":"Venstrom","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.09.006_bib0124","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.bbmt.2010.03.004","article-title":"Donor KIR Genes 2DL5A, 2DS1 and 3DS1 are associated with a reduced rate of leukemia relapse after HLA-identical sibling stem cell transplantation for acute myeloid leukemia but not other hematologic malignancies","volume":"16","author":"Stringaris","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.09.006_bib0125","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/leu.2008.365","article-title":"KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia","volume":"23","author":"Willemze","year":"2009","journal-title":"Leukemia"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.09.006_bib0126","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1038\/s41409-021-01259-0","article-title":"Natural killer cell alloreactivity in HLA-haploidentical hematopoietic transplantation: a study on behalf of the CTIWP of the EBMT","volume":"56","author":"Ruggeri","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.09.006_bib0127","doi-asserted-by":"crossref","first-page":"S227","DOI":"10.1016\/j.jtct.2023.12.296","article-title":"SAR445419 off-the-shelf natural killer cells are safe and show efficacy signal in relapsed\/refractory acute myeloid leukemia","volume":"30","author":"Vasu","year":"2024","journal-title":"Transplantat Cellular Ther"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.09.006_bib0128","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1182\/blood-2023-190399","volume":"142","author":"McCloskey","year":"2023","journal-title":"Blood"},{"issue":"633","key":"10.1053\/j.seminhematol.2024.09.006_bib0129","doi-asserted-by":"crossref","first-page":"eabm1375","DOI":"10.1126\/scitranslmed.abm1375","article-title":"Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemia","volume":"14","author":"Berrien-Elliott","year":"2022","journal-title":"Sci Transl Med"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.09.006_bib0130","doi-asserted-by":"crossref","DOI":"10.1172\/JCI154334","article-title":"Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse","volume":"132","author":"Shapiro","year":"2022","journal-title":"J Clin Invest"},{"issue":"19","key":"10.1053\/j.seminhematol.2024.09.006_bib0131","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1182\/blood-2013-10-533398","article-title":"CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets","volume":"123","author":"Gleason","year":"2014","journal-title":"Blood"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.09.006_bib0132","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1182\/bloodadvances.2017012369","article-title":"161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDS","volume":"2","author":"Sarhan","year":"2018","journal-title":"Blood Adv"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.09.006_bib0133","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1038\/s41587-022-01626-2","article-title":"Control of acute myeloid leukemia by a trifunctional NKp46-CD16a-NK cell engager targeting CD123","volume":"41","author":"Gauthier","year":"2023","journal-title":"Nat Biotechnol"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.09.006_bib0134","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41408-022-00660-2","article-title":"Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia","volume":"12","author":"Albinger","year":"2022","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.09.006_bib0135","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.cell.2009.05.045","article-title":"CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells","volume":"138","author":"Majeti","year":"2009","journal-title":"Cell"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.09.006_bib0136","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2009.05.046","article-title":"CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis","volume":"138","author":"Jaiswal","year":"2009","journal-title":"Cell"},{"issue":"15","key":"10.1053\/j.seminhematol.2024.09.006_bib0137","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1200\/JCO.22.01794","article-title":"Magrolimab in combination with azacitidine in patients with higher-risk myelodysplastic syndromes: final results of a phase IB study","volume":"41","author":"Sallman","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2024.09.006_bib0138","first-page":"S138","article-title":"Magrolimab vs placebo in combination with venetoclax and azacitidine in previously untreated patients with acute myeloid leukemia who are ineligible for intensive chemotherapy: the ENHANCE-3 study","volume":"422242","author":"Daver","year":"2024","journal-title":"EHA 2024 Annual Meeting"},{"issue":"714","key":"10.1053\/j.seminhematol.2024.09.006_bib0139","doi-asserted-by":"crossref","first-page":"eadi1145","DOI":"10.1126\/scitranslmed.adi1145","article-title":"Epitope base editing CD45 in hematopoietic cells enables universal blood cancer immune therapy","volume":"15","author":"Wellhausen","year":"2023","journal-title":"Sci Transl Med"},{"key":"10.1053\/j.seminhematol.2024.09.006_bib0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2023.101135","article-title":"Development of a gene edited next-generation hematopoietic cell transplant to enable acute myeloid leukemia treatment by solving off-tumor toxicity","volume":"31","author":"Lydeard","year":"2023","journal-title":"Mol Ther Methods Clin Dev"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196324001094?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196324001094?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T17:52:54Z","timestamp":1734025974000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196324001094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":140,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S0037196324001094"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2024.09.006","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cellular and immunotherapies for myelodysplastic syndromes","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2024.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}